A CONTROLLED DOSE-RANGING STUDY OF REMOXIPRIDE AND HALOPERIDOL IN SCHIZOPHRENIA - A CANADIAN MULTICENTER TRIAL

被引：38

作者：

LAPIERRE, YD

NAIR, NPV

CHOUINARD, G

AWAD, AG

SAXENA, B

JONES, B

MCCLURE, DJ

BAKISH, D

MAX, P

MANCHANDA, R

BEAUDRY, P

BLOOM, D

ROTSTEIN, E

ANCILL, R

SANDOR, P

SLADENDEW, N

DURAND, C

CHANDRASENA, R

HORN, E

ELLIOT, D

DAS, M

RAVINDRAN, A

MATSOS, G

机构：

[1] RIVERVIEW HOSP, PORT COQUITLAN, BC, CANADA

[2] VICTORIA HOSP, LONDON N6A 4G5, ONTARIO, CANADA

[3] TORONTO WESTERN HOSP, TORONTO M5T 2S8, ONTARIO, CANADA

[4] ALLAN MEM INST PSYCHIAT, MONTREAL H3A 1A1, QUEBEC, CANADA

[5] LOUIS H LAFONTAINE HOSP, MONTREAL H1N 3M5, QUEBEC, CANADA

[6] HAMILTON PSYCHIAT HOSP, HAMILTON, ONTARIO, CANADA

[7] UNIV BRITISH COLUMBIA, VANCOUVER V6T 1W5, BC, CANADA

[8] VANCOUVER GEN HOSP, VANCOUVER V5Z 1M9, BC, CANADA

[9] ST THOMAS HOSP, ST THOMAS, ONTARIO, CANADA

[10] PIERRE JANET, HULL, ENGLAND

[11] ASTRA PHARMA INC, MISSISSAUGA, ONTARIO, CANADA

[12] DOUGLAS HOSP, MONTREAL H4H 1R3, QUEBEC, CANADA

[13] WELLESLEY COLL HOSP, TORONTO M4Y 1J3, ONTARIO, CANADA

来源：

ACTA PSYCHIATRICA SCANDINAVICA | 1990年 / 82卷

关键词：

dose ranging; remoxipride; ‐haloperidol; schizophrenia;

D O I：

10.1111/j.1600-0447.1990.tb05293.x

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Abstract The efficacy and side‐effect profile for three dose ranges of remoxipride were compared with haloperidol in 242 schizophrenic inpatients in 13 centres. All patients were in a productive phase of schizophrenia according to DSM‐III criteria. Relative efficacy of low dose (30–90 mg daily) vs middle dose (120–240 mg daily) vs high dose (300–600 mg daily) was compared with the standard dose of haloperidol (15–45 mg daily), as were the side effects. It was concluded that the therapeutic efficacy of remoxipride was comparable to that of haloperidol for acute episodes of schizophrenia; that the low dose range was significantly less effective than the higher ranges; that there was a clear advantage of remoxipride over haloperidol with respect to incidence and severity of extrapyramidal symptoms. The general I safety profile of remoxipride as assessed from clinical chemistry, haematology, and cardiovascular variables suggests that remoxipride in the dose ranges studied can be used safely for the treatment of schizophrenic patients. Copyright © 1990, Wiley Blackwell. All rights reserved

引用

页码：72 / 77

页数：6

共 9 条

[1]

American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd

[2]

[Anonymous], 1976, ECDEU ASSESSMENT MAN

[3] NOSIE-30 - A TREATMENT-SENSITIVE WARD BEHAVIOR SCALE [J].